Therapeutic Asset Ratings

9,928 results matching 1 filter

91,564 assets · 7,904 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Blu-701 Respiratory Tract Neoplasm	Blueprint Medicines Corporation	P1	CC (43)
Bmn 255 Nephrolithiasis	BioMarin Pharmaceutical	P1	CC (43)
Bmn 255 Metabolic Dysfunction-Associated Steatotic Liver Disease	BioMarin Pharmaceutical	P1	CC (43)
Bmn 349 Alpha 1-Antitrypsin Deficiency	BioMarin Pharmaceutical	P1	CC (43)
BMS-986353 is an investigational CD19-targeted CAR T-cell product. The CD19-specific CAR consists of a single-chain variable fragment (scFv) binding domain derived from a CD19-specific monoclonal antibody (mAb; FMC63), an IgG-derived hinge region, a CD28 transmembrane domain, and the CD137 (41BB) and CD3? chain signaling domains. The third-generation SIN lentiviral vector, which encodes the CAR domains described above, also encodes a truncated human epidermal growth factor receptor (EGFRt) that is expressed separately from the CD19 CAR on the T cell surface Myasthenia Gravis	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	P1	CC (43)
BMS-986463 Ovarian Serous Adenocarcinoma	Bristol-Myers Squibb	P1	CC (43)
BMS-986500 Ovarian Cancer	Bristol-Myers Squibb	P1	CC (43)
BMS-986504 Malignant Pleural Mesothelioma	Memorial Sloan Kettering Cancer Center	P1	CC (43)
Bosentan Malignant Pancreatic Neoplasm	City of Hope Medical Center	P1	CC (43)
Bosentan Exocrine Pancreatic Carcinoma	City of Hope Medical Center	P1	CC (43)
Bosutinib Acute Myeloid Leukemia	City of Hope Medical Center	P1	CC (43)
Botensilimab Angiosarcoma	Agenus Inc.	P1	CC (43)
Botensilimab Fibrolamellar Hepatocellular Carcinoma	Agenus Inc.	P1	CC (43)
bp1001-a Ovarian Carcinoma	Bio-Path Holdings, Inc.	P1	CC (43)
BP1002 Acute Myeloid Leukemia	Bio-Path Holdings, Inc.	P1	CC (43)
BP1002 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Bio-Path Holdings, Inc.	P1	CC (43)
BP1002 Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	Bio-Path Holdings, Inc.	P1	CC (43)
BP1002 Diffuse Large B-Cell Lymphoma	Bio-Path Holdings, Inc.	P1	CC (43)
BP1002 Peripheral T-Cell Lymphoma, Not Otherwise Specified	Bio-Path Holdings, Inc.	P1	CC (43)
bp1002; liposomal bcl-2 antisense oligodeoxynucleotide Acute Myeloid Leukemia	Bio-Path Holdings, Inc.	P1	CC (43)
Bpi-421286 Cancer	Betta Pharmaceuticals Co., Ltd.	P1	CC (43)
Bpi-452080 Von Hippel-Lindau Disease	Betta Pharmaceuticals Co., Ltd.	P1	CC (43)
Brexpiprazole Long-Acting Schizophrenia	Sichuan Kelun Pharmaceutical Co.,Ltd.	P1	CC (43)
Brodalumab Lip And Oral Cavity Carcinoma	Brian Henick, MD	P1	CC (43)
BSB-2002 Acute Myeloid Leukemia	BlueSphere Bio, Inc	P1	CC (43)

Showing 1351 to 1375 of 9,928 assets

PreviousPage 55 of 398Next